ALEXANDER G. VANDEVELDE, M.D.; ARTHUR A. MAUCERI, M.D.; JOSEPH E. JOHNSON III, M.D., F.A.C.P.
Twenty-two patients with deep-seated mycotic infections were treated with 5-fluorocytosine: in 8 patients the infection was caused by species of Crypfococcus; in 8, Candida albicans; in 3, Phialophora species; in 1, Torulopsis glabrata; in 1, Sporothrix schenckii; and in 1, Aspergillus fumigatus. Apparent cure was achieved in 11 patients; 6 more showed significant improvement, but 5 were judged to be treatment failures. In some instances this new fungal antimetabolite was effective in cases that had not responded to amphotericin B. Because oral administration produces effective tissue levels, and side effects are rare and usually transient, this drug is a welcome addition to the therapeutic armamentarium for mycotic infections. It may become the drug of choice for the treatment of chromoblastomycosis.
VANDEVELDE AG, MAUCERI AA, JOHNSON JE. 5-Fluorocytosine in the Treatment of Mycotic Infections. Ann Intern Med. ;77:43–50. doi: 10.7326/0003-4819-77-1-43
Download citation file:
Published: Ann Intern Med. 1972;77(1):43-50.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use